FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308365863> ?p ?o ?g. }

• W4308365863 endingPage "575" @default.
• W4308365863 startingPage "566" @default.
• W4308365863 abstract "A new water-soluble formulation with ciclopirox has shown a higher penetration than other ciclopirox nail lacquers currently marketed, thus providing a higher concentration of ciclopirox into the nail.To evaluate the efficacy and safety of a new ciclopirox nail hydrolacquer compared with its vehicle and an active comparator (hydroxypropyl chitosan-based 80 mg/g ciclopirox nail lacquer) for the treatment of toenail fungal infection.Phase III, multicenter, randomised, double-blind, clinical trial in patients with distal mild to moderate toenail onychomycosis due to dermatophyte fungi. Patients were randomised to apply topically a ciclopirox nail hydrolacquer, its vehicle or a reference product once daily for 48 weeks with a follow-up period of 4 weeks up to week 52.A total of 381 patients were included. No statistically significant differences were observed between patient groups in the proportion of subjects achieving a complete cure. At week 52, a higher percentage of patients in the ciclopirox nail hydrolacquer group achieved a mycological cure (negative for culture and DTS/KOH test, with results: 32.0% ciclopirox nail hydrolacquer, 23.2% vehicle and 27% reference product, respectively), and similar results were found for improvement (mycological cure and reduction of diseased nail ≥20%, with results: 27.2% ciclopirox nail hydrolacquer, 21.6% vehicle and 20.6% reference product, respectively). Regarding mycological results, only ciclopirox nail hydrolacquer demonstrated significant statistical superiority versus vehicle negativizing dermatophyte culture (p = .039) with no recurrences, relapses or re-infections in a four-week follow-up patients with complete cure. The safety profile was comparable to the vehicle and reference product and consistent with the previously reported.A new water-soluble formulation for a ciclopirox nail lacquer showed similar efficacy to the reference product to eradicate toenail onychomycosis and superiority in the mycological cure defined by negative culture, thus preventing reinfections and recurrences. Efficacy and safety data demonstrate the positive benefit-risk profile of this new topical antifungal preparation. [Correction added on 13 April 2023, after first online publication: The results and conclusions in the Abstract contained incorrect information and were revised in this version.]." @default.
• W4308365863 created "2022-11-11" @default.
• W4308365863 creator A5001785911 @default.
• W4308365863 creator A5003637543 @default.
• W4308365863 creator A5015235416 @default.
• W4308365863 creator A5022654117 @default.
• W4308365863 creator A5023443155 @default.
• W4308365863 creator A5041562111 @default.
• W4308365863 creator A5052947429 @default.
• W4308365863 creator A5070188206 @default.
• W4308365863 creator A5071849507 @default.
• W4308365863 creator A5090485454 @default.
• W4308365863 date "2022-11-17" @default.
• W4308365863 modified "2023-10-16" @default.
• W4308365863 title "Efficacy and safety of a new medicated nail hydrolacquer in the treatment of adults with toenail onychomycosis: A randomised clinical trial" @default.
• W4308365863 cites W1914355256 @default.
• W4308365863 cites W1960538084 @default.
• W4308365863 cites W1974097821 @default.
• W4308365863 cites W1982213437 @default.
• W4308365863 cites W1986773685 @default.
• W4308365863 cites W1996832140 @default.
• W4308365863 cites W2023788932 @default.
• W4308365863 cites W2032250968 @default.
• W4308365863 cites W2032645908 @default.
• W4308365863 cites W2039269979 @default.
• W4308365863 cites W2046365958 @default.
• W4308365863 cites W2054818988 @default.
• W4308365863 cites W2059619997 @default.
• W4308365863 cites W2075606510 @default.
• W4308365863 cites W2079167414 @default.
• W4308365863 cites W2094873820 @default.
• W4308365863 cites W2101260926 @default.
• W4308365863 cites W2105622854 @default.
• W4308365863 cites W2109533181 @default.
• W4308365863 cites W2143470897 @default.
• W4308365863 cites W2150051883 @default.
• W4308365863 cites W2161090240 @default.
• W4308365863 cites W2301016254 @default.
• W4308365863 cites W2421260200 @default.
• W4308365863 cites W2502043390 @default.
• W4308365863 cites W2578572252 @default.
• W4308365863 cites W2792607011 @default.
• W4308365863 cites W2889955623 @default.
• W4308365863 cites W2904996155 @default.
• W4308365863 cites W3009134618 @default.
• W4308365863 cites W3047461257 @default.
• W4308365863 cites W3156825476 @default.
• W4308365863 cites W3211619877 @default.
• W4308365863 cites W4229444975 @default.
• W4308365863 doi "https://doi.org/10.1111/myc.13543" @default.
• W4308365863 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36336989" @default.
• W4308365863 hasPublicationYear "2022" @default.
• W4308365863 type Work @default.
• W4308365863 citedByCount "0" @default.
• W4308365863 crossrefType "journal-article" @default.
• W4308365863 hasAuthorship W4308365863A5001785911 @default.
• W4308365863 hasAuthorship W4308365863A5003637543 @default.
• W4308365863 hasAuthorship W4308365863A5015235416 @default.
• W4308365863 hasAuthorship W4308365863A5022654117 @default.
• W4308365863 hasAuthorship W4308365863A5023443155 @default.
• W4308365863 hasAuthorship W4308365863A5041562111 @default.
• W4308365863 hasAuthorship W4308365863A5052947429 @default.
• W4308365863 hasAuthorship W4308365863A5070188206 @default.
• W4308365863 hasAuthorship W4308365863A5071849507 @default.
• W4308365863 hasAuthorship W4308365863A5090485454 @default.
• W4308365863 hasBestOaLocation W43083658631 @default.
• W4308365863 hasConcept C126322002 @default.
• W4308365863 hasConcept C16005928 @default.
• W4308365863 hasConcept C191897082 @default.
• W4308365863 hasConcept C192562407 @default.
• W4308365863 hasConcept C2777220567 @default.
• W4308365863 hasConcept C2777852167 @default.
• W4308365863 hasConcept C535046627 @default.
• W4308365863 hasConcept C71924100 @default.
• W4308365863 hasConceptScore W4308365863C126322002 @default.
• W4308365863 hasConceptScore W4308365863C16005928 @default.
• W4308365863 hasConceptScore W4308365863C191897082 @default.
• W4308365863 hasConceptScore W4308365863C192562407 @default.
• W4308365863 hasConceptScore W4308365863C2777220567 @default.
• W4308365863 hasConceptScore W4308365863C2777852167 @default.
• W4308365863 hasConceptScore W4308365863C535046627 @default.
• W4308365863 hasConceptScore W4308365863C71924100 @default.
• W4308365863 hasIssue "7" @default.
• W4308365863 hasLocation W43083658631 @default.
• W4308365863 hasLocation W43083658632 @default.
• W4308365863 hasOpenAccess W4308365863 @default.
• W4308365863 hasPrimaryLocation W43083658631 @default.
• W4308365863 hasRelatedWork W134615286 @default.
• W4308365863 hasRelatedWork W1497533237 @default.
• W4308365863 hasRelatedWork W2090437230 @default.
• W4308365863 hasRelatedWork W2098330375 @default.
• W4308365863 hasRelatedWork W2331656415 @default.
• W4308365863 hasRelatedWork W2461779847 @default.
• W4308365863 hasRelatedWork W2761171778 @default.
• W4308365863 hasRelatedWork W4211182850 @default.
• W4308365863 hasRelatedWork W4231542811 @default.
• W4308365863 hasRelatedWork W87364043 @default.
• W4308365863 hasVolume "66" @default.

• next